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Abstract
Background: Malaria treatment efforts are hindered by the rapid emergence and spread of drug resistant parasites.
Simple assays to monitor parasite drug response in direct patient samples (ex vivo) can detect drug resistance
before it becomes clinically apparent, and can inform changes in treatment policy to prevent the spread of
resistance.
Methods: Parasite drug responses to amodiaquine, artemisinin, chloroquine and mefloquine were tested in
approximately 400 Plasmodium falciparum malaria infections in Thiès, Senegal between 2008 and 2011 using a
DAPI-based ex vivo drug resistance assay. Drug resistance-associated mutations were also genotyped in pfcrt and
pfmdr1.
Results: Parasite drug responses changed between 2008 and 2011, as parasites became less sensitive to
amodiaquine, artemisinin and chloroquine over time. The prevalence of known resistance-associated mutations also
changed over time. Decreased amodiaquine sensitivity was associated with sustained, highly prevalent mutations in
pfcrt, and one mutation in pfmdr1 – Y184F – was associated with decreased parasite sensitivity to artemisinin.
Conclusions: Directly measuring ex vivo parasite drug response and resistance mutation genotyping over time are
useful tools for monitoring parasite drug responses in field samples. Furthermore, these data suggest that the use
of amodiaquine and artemisinin derivatives in combination therapies is selecting for increased drug tolerance
within this population.
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Background
Plasmodium falciparum malaria has an enormous public
health impact, infecting millions and killing hundreds of
thousands of people each year [1]. Drug resistance fur-
ther magnifies the burden of this disease, as resistant
malaria parasites have been selected by nearly every
anti-malarial drug used to date. Reports of parasites with
reduced susceptibility to artemisinin combination ther-
apy (ACT) [2,3] underscore the importance of closely
monitoring parasite drug responses and optimizing
control strategies to quickly identify and prevent the
spread of resistant parasites, particularly on the African
continent [4].
Malaria drug resistance monitoring involves directly
measuring parasite drug responses, or indirectly measur-
ing the prevalence of resistance-associated mutations
within a parasite population. Ex vivo drug resistance as-
says measure drug response in parasites taken directly
from infected patients, without prior culture adaptation.
These assays allow the components of combination ther-
apies to be tested individually against parasites, and they
can detect decreases in drug efficacy before resistance
becomes clinically evident and widespread [5]. Many
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ance in both laboratory and field settings [6-13]. In
addition, mutations in a number of parasite genetic loci
have been shown to contribute to anti-malarial drug re-
sistance, including pfcrt and pfmdr1, among others [14].
Monitoring the prevalence of these mutations consist-
ently over several years can reveal trends in allele selec-
tion within a population over time, and can extend the
therapeutic life of current and future treatments [15,16].
The motivation for this study was to ask whether the
malaria parasites circulating in Thiès, Senegal were be-
coming more or less resistant to anti-malarial drugs over
time, and whether changes in parasite drug response
could be explained by known drug resistance-associated
mutations. Drug use in Senegal changed from chloro-
quine monotherapy to sulphadoxine, pyrimethamine and
amodiaquine in 2003, and again to ACT (predominantly
artesunate-amodiaquine in Thiès) in 2006 [17]. Previous
drug resistance monitoring efforts in Senegal have fo-
cused on directly testing parasite drug sensitivity [11,18],
measuring the prevalence of resistance-associated muta-
tions [19,20], or both. The aim of this study was to
measure both parasite drug sensitivity and resistance
mutation prevalence over time, in order to understand
how parasites in Senegal may be changing in response to
drug treatment.
Methods
Study population
Individuals seeking treatment for uncomplicated P. fal-
ciparum malaria at the Section de Lutte Antiparasitaire
(SLAP) clinic in Thiès, Senegal, during the fall transmis-
sion seasons of 2008-2011 were tested for malaria infec-
tion by microscopy and rapid diagnostic test (RDT).
Plasmodium falciparum-positive patients were eligible
for screening if they met the criteria described below
and the patient or legal guardian provided informed
written consent or assent. Eligibility criteria were: pa-
tients older than two years, axillary temperature above
37.5°C or history of fever within the preceding 24 hours,
infection with only P. falciparum, no recent anti-
malarial drug use, and a haemoglobin level greater than
6 g/dL. Patients with symptoms of severe malaria were
excluded and referred to the Thiès regional hospital for
appropriate care. Study protocols and informed consent
documents were approved by the Institutional Review
Boards of the Senegal Ministry of Health IRB Committee
and the Harvard School of Public Health (Senegal Proto-
col #16330; Harvard Protocol #P10256-127).
Among the 831 patients with uncomplicated malaria
screened at the SLAP clinic between 2008 and 2011, a
subset of 397 patient samples were tested for parasite
drug response using the DAPI ex vivo assay (Table 1).
The subset of patients that were tested was comparable
to the larger set of screened patients with respect to
demographic parameters (age, gender) and clinical char-
acteristics (temperature, haematocrit, weight) with the
exception of parasitaemia.
Sample collection and DAPI ex vivo testing
From each subject, 5-10 mL venous blood were collected
and processed on the same day. Approximately 1 mL of
blood was spotted onto Whatman FTA™ filter paper
cards for subsequent DNA extraction; the remaining
blood was spun at 1,500 rpm for 10 minutes, plasma
and buffy coat were removed, and infected red blood
cells were washed twice with unsupplemented RPMI
media. Aliquots of each sample were cryopreserved in
Glycerolyte 57 (Fenwal) supplemented with AB
+ serum,
for subsequent culture adaptation and in vitro repeat
drug testing.
Parasites were drug tested using the previously de-
scribed DAPI ex vivo assay [11]. Briefly, 180 μLo fs u p p l e -
mented RPMI media containing parasitized erythrocytes
at 2% haematocrit were distributed into 96-well plates pre-
loaded with 20 μL serial dilutions of amodiaquine (USP
1031004), artemisinin (Sigma A5430), chloroquine (Sigma
C6628) and mefloquine (Sigma M2319). Drug concentra-
tions ranged from less than 1 nM to greater than 1 μM
and each plate included 6-8 negative control wells with
media only. Plates contained two wells of each drug
concentration, were prepared in a single batch, and
were frozen prior to use. When possible, samples with
parasitaemia greater than 1% were diluted into
leukocyte-free donor O
+ erythrocytes to a final plating
parasitaemia of 0.4-1%.
Parasites were cultured 48-72 hours at 37°C under
standard gas conditions (1% O2,5 %C O 2, 94% N2) before
addition of 4′,6-diamidino-2-phenylindole (DAPI) solu-
tion, as described previously [8,11]. Data were collected
by measuring relative fluorescence units (RFUs) using a
Fluoroskan plate reader (Thermo Scientific; ex 358 nm,
Table 1 Clinical parameters in screened patients and the
subset tested using the DAPI ex vivo assay
All screened
patients
DAPI tested
patients
P
Number 831 397 -
Gender (% male) 66 64 0.59
Age (years) 20 (15, 28) 20 (14, 26) 0.24
Weight (kg) 55 (42, 65) 55 (39, 65) 0.46
Temperature (°C) 38.2 (37.2, 39.7) 38.4 (37.3, 40.0) 0.25
Haematocrit (%) 38 (32, 40) 38 (32, 40) 0.79
Parasitaemia (%) 0.50 (0.20, 1.00) 0.61 (0.40, 1.10) <.0001
Median values (with interquartile ranges) are reported for age, weight,
temperature, haematocrit and parasitaemia. P-values were calculated using
Pearson X
2 for categorical variables, and Wilcox rank-sum test for
continuous variables.
Van Tyne et al. Malaria Journal 2013, 12:441 Page 2 of 10
http://www.malariajournal.com/content/12/1/441em 461 nm). 3D7 parasites were tested on each batch of
drug plates to control for batch variation, and there were
no consistent trends toward increased resistance among
parasites tested later each season, suggesting minimal
batch degradation.
DNA extraction, clonality of infection and HRM
genotyping
DNA was extracted from 4-5 circular 6 mm punches of
blood preserved on Whatman FTA™ filter paper cards
using either a QIAmp DNA Blood Mini Kit (Qiagen) or
a Maxwell DNA IQ Casework Sample Kit (Promega).
Parasite genomic DNA was quantified by quantitative
Real-Time PCR (qPCR) [21], and clonality of infection,
defined as monoclonal or polyclonal, was assessed using
the 24-SNP molecular barcode [21].
High resolution melt (HRM) technology was used to
genotype a set of single nucleotide polymorphisms
(SNPs) associated with reduced drug sensitivity [19].
Mutations were detected based on changes in DNA se-
quence; in the text, mutations are referred to by the cor-
responding amino acid changes. Briefly, 0.01 ng of
parasite template, as quantified by qPCR [21], was used
for each 5 μL reaction, which included 2.5× LightScanner
Master Mix with LCGreen Plus dsDNA dye (BioFire
Diagnostics, Inc.). HRM analysis and genotype determin-
ation was performed on a LightScanner-384 (BioFire
Diagnostics, Inc.). The HRM method can determine geno-
types from as little as 10 pg of parasite DNA and can de-
tect mutant alleles present at less than 1% [19].
Culture adaptation and in vitro drug testing
To assess whether ex vivo drug responses were reprodu-
cible in vitro, 16 parasite isolates derived from monoclo-
nal infections collected in 2009 were culture adapted
and re-tested in vitro. Culturing was conducted under
standard conditions [22] with gentle shaking at 55 rpm.
Parasites were in vitro drug tested against a panel of
known anti-malarials using a standard hypoxanthine in-
corporation assay [7], or a SYBR Green I-based drug
assay [23] with modifications for 384-well format.
Calculation of IC50 values and data exclusion
Fluorescence data from drug assays were analysed using
GraphPad Prism (San Diego, CA) through a four-
parameter, log-logistic nonlinear regression of fluores-
cence intensity versus log10-transformed drug concentra-
tions. To include control wells with no drug in the
analysis, 1 nM was added to each concentration value.
Dose-response curves were visually inspected for fit of
the sigmoidal dose-response model. Among 397 patient
samples tested using the DAPI ex vivo assay, 25 samples
were considered assay failures due to no parasite growth
or assay contamination and were excluded from further
analysis. An additional two patient samples with a plat-
ing parasitaemia below 0.1% and 30 samples with a plat-
ing parasitaemia above 1.5% were excluded, because
there was no clear association between plating parasit-
aemia and fluorescence intensity in the no-drug wells,
perhaps due to insufficient growth or saturation. This
left 340 patient samples from which parasite response to
at least one anti-malarial drug was determined.
Drug curves that did not exhibit the standard sig-
moidal dose-response shape were classified as either fit-
ting an exponential or linear decay model, and had their
IC50 values estimated through these alternative models,
or were excluded. When IC50 values from technical rep-
licates could not be estimated due to a single outlier
point, this point was excluded.
Data and statistical analysis
Dynamic range of the DAPI ex vivo assay was assessed by
calculating the signal-to-noise ratio (SNR) and Z’-factor of
each assay. SNR was measured by dividing fluorescence
signal (RFUs) from no-drug wells by fluorescence signal
from maximum drug wells. The median signal-to-noise
ratio (SNR) among all assays was 3:1 (Interquartile
Range=2:1, 5:1). Z’-factor was calculated using the follow-
ing equation: Z’=1- [(3 standard deviations of positive
controls+3 standard deviations of negative controls)/
absolute difference between negative and positive con-
trols] [24]. The median Z’-factor among all assays was
0.61; Z’-factors greater than 0 are considered acceptable,
and Z’-factors greater than 0.5 are considered excellent
[24]. Reliability of the DAPI ex vivo assay was measured
by evaluating agreement between technical replicates in
the untransformed scale using the intraclass correlation
coefficient (ICC) for agreement. Only sigmoidal curves
were analysed, to avoid biases due to lack of fitness of dif-
ferent IC50 curve-fitting models. For all drugs, mean
differences in IC50 values between replicates were approxi-
mately zero, as expected. Except for a few outliers (fewer
than five points for each drug), differences between repli-
cates were small compared with the IC50 range of each
drug.
Statistical analyses were performed in GraphPad Prism
(v5.0d, San Diego, CA) and R-2.11.1. IC50 values measured
ex vivo were compared to in vitro IC50 values from
culture-adapted parasites by calculating the intraclass cor-
relation coefficient (ICC) for consistency (R package irr),
and by linear regression. To monitor population drug sen-
sitivity, IC50 variations over time were measured through
linear regression with log10-transformed IC50 values. Pri-
mary analysis focused on non-linear trends (using indica-
tor variables for years) but results were confirmed by
assessing linear trends. Multiple regression models were
used to measure whether IC50 values changed significantly
over time after accounting for the effect of potential
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and temperature). Since parasites with reduced drug sensi-
tivity may first arise in subpopulations that exhibit larger
IC50 values, the 90
th percentile among all IC50 values is
reported for each year. Changes in the prevalence of drug
resistance markers over time were measured by Fisher-
Hamilton exact test, and 95% confidence intervals for
marker prevalence are based on the logit (R package
Figure 1 Validation of the DAPI ex vivo drug assay. A. Fluorescence intensity of maximum growth wells versus initial parasitaemia for
parasites tested in the DAPI ex vivo drug assay. Pearson ρ=0.47, linear slope P< 0.0001. B. Box plots showing signal-to-noise ratio (SNR) and
Z’-factor for all assays. C-F. Bland-Altman plots showing differences between IC50 values of each technical replicate vs. average IC50 values for
amodiaquine (C), artemisinin (D), chloroquine (E), and mefloquine (F). Horizontal lines indicate the mean difference in IC50 values between
replicates. Intra-class correlation coefficients (ICC, with corresponding 95% confidence intervals) are displayed on each graph. G-I. Comparison of
ex vivo with in vitro IC50 values for artemisinin (G), chloroquine (H), and mefloquine (I), among culture-adapted monoclonal parasites collected in
2009. Mean in vitro IC50 values are plotted with error bars showing the standard error of at least two biological replicates. ρ denotes the Pearson
correlation coefficient.
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occurrence of drug resistance-associated mutations in
pfcrt and pfmdr1 were assessed through the Wilcoxon
rank-sum test.
Results
DAPI ex vivo assay validation
The usefulness of the DAPI-based ex vivo assay for mon-
itoring drug sensitivity among the parasites circulating
in Thiès, Senegal was assessed by measuring the dy-
namic range and reliability of the assay. This ex vivo
assay could be used to accurately calculate anti-malarial
50-percent inhibitory concentrations (IC50 values) in dir-
ect patient samples, as evidenced by the dynamic range
of the assay (Figure 1A and B), and by testing for repro-
ducibility between technical replicates (Figure 1C-F). A
subset of parasites derived from monoclonal infections
was culture adapted and retested for their susceptibility
to chloroquine, mefloquine and artemisinin in vitro
(Figure 1G-I). In vitro drug responses were highly cor-
related with ex vivo responses, with systematic differ-
ences in scale presumably due to the technical
differences between assays. Amodiaquine was not in-
cluded in the in vitro testing because all parasites tested
were sensitive to the drug, and the range of observed
IC50 values was narrow. Overall, the DAPI ex vivo assay
provided valid and consistent results, and could, there-
fore, be used as a tool to directly measure malaria para-
site drug responses in patient samples.
Distribution of parasite drug responses across years
The DAPI ex vivo drug assay was used to compare para-
site drug responses to amodiaquine, artemisinin, chloro-
quine and mefloquine among all parasites tested between
AB
CD
Figure 2 Changes in ex vivo parasite sensitivity over time. IC50 values among parasites collected in Thiès, Senegal and tested against
amodiaquine (A), artemisinin (B), chloroquine (C), and mefloquine (D). The number of samples tested each year is indicted in parentheses below
each plot. Horizontal lines indicate median IC50 values. The asterisk in panel A indicates an IC50 value off the scale (amodiaquine IC50 =1140 nM).
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site IC50 values increased for amodiaquine, artemisinin
and chloroquine (P<0.001 for linear and non-linear
trends and in both crude and adjusted analyses). Parasite
IC50 values for mefloquine also changed, but after adjust-
ing for confounders only a non-linear trend in drug re-
sponses over time was detected. The 90
th percentile IC50
values, representing the most resistant parasites observed
each year, also increased between 2008 and 2011 for amo-
diaquine, artemisinin and chloroquine (Table 2). Finally,
there was a large range of parasite responses to amodia-
quine and artemisinin, two anti-malarials that have been
used in combination therapies in this area since 2006 [17].
IC50 values ranged from 1 nM to over 50 nM for amodia-
quine (except for one outlier in 2008), and from 1 nM to
over 70 nM for artemisinin.
Prevalence of resistance-associated mutations over time
In addition to directly testing parasite drug responses,
known drug resistance-associated mutations in pfcrt and
pfmdr1 were genotyped in order to assess changes in the
prevalence of these mutations over time. No change in
the prevalence of the mutant haplotype at protein posi-
tions 72-76 within pfcrt was detected (Figure 3A). This
haplotype was almost always inherited along with the
A220S mutation in pfcrt, and both mutations remained
above 50% prevalence in this population, in contrast to
other studies within Senegal [20], and elsewhere in
Africa [25]. Prevalence of the N326S mutation, however,
did change over time (P <0.05), and was not linked to
the other typed mutations within pfcrt.
While the mutations typed in pfcrt either stayed the
same or increased in prevalence over time, the muta-
tions typed in pfmdr1 showed two distinct patterns in
their prevalence over the four years studied (Figure 3B).
The N86Y and N1042D mutations both decreased in
prevalence between 2008 and 2011 (P<0.05). By 2011,
the N86Y mutation was detected in fewer than 5% of
parasites, and the N1042D mutation was absent from
the population sampled in both 2010 and 2011. Con-
versely, the Y184F mutation more than doubled in
prevalence, from approximately 30% in 2008 to greater
than 70% in 2011 (P <0.05).
Correlations between resistance mutations and ex vivo
drug responses
To assess whether the use of amodiaquine and artemisi-
nin derivatives could be driving the observed changes in
resistance mutation prevalence, associations between
mutations and IC50 values were examined. The occur-
rence of mutant genotypes at pfcrt 72-76, A220S, and
N326S were all associated with increased amodiaquine
IC50 values (Table 3). These same pfcrt mutations were
also associated with higher chloroquine IC50 values, pos-
sibly due to cross-resistance between chloroquine and
amodiaquine (Pearson ρ= 0.6). The mutant 72-76 haplo-
type and A220S were also associated with artemisinin
sensitivity, and none of the typed pfcrt mutations were
associated with mefloquine response.
Associations between mutations in pfmdr1 and para-
site drug response were also detected. Parasites with
wild-type alleles at amino acid positions 86 and 1042, as
well as parasites with the mutant allele at position 184,
had increased artemisinin IC50 values (Table 3). Artemi-
sinin was the only drug associated with the Y184F muta-
tion in this population – this mutation was not
associated with amodiaquine, chloroquine, or meflo-
quine responses. No significant association was seen be-
tween amodiaquine or chloroquine responses and any of
the mutations typed in pfmdr1, in contrast to previous
findings [26-28], and perhaps due to a small number of
parasites possessing the N86Y and N1042D mutations.
Stratifying first on the pfcrt 72-76 haplotype did not re-
veal an association between amodiaquine or chloroquine
and any of the pfmdr1 mutations that were genotyped.
Finally, higher mefloquine IC50 values were also associ-
ated with the wild-type allele at position 86 within
pfmdr1; this was the only significant association between
any of the typed mutations and mefloquine IC50 values.
Table 2 Parasite drug responses measured in the DAPI
ex vivo assay
2008 2009 2010 2011
(N= 86) (N=78) (N= 81) (N=82)
Amodiaquine
Median IC50 9.6 6.5 11.2 14.5
IC50 Range 1.6, 1140 3.2, 36.7 1.0, 45.3 2.3, 53.7
90
th percentile IC50 24.0 11.8 22.2 35.4
Artemisinin
Median IC50 3.2 8.1 9.9 10.1
IC50 Range 1.1, 28.8 1.8, 36.7 1.9, 38.0 1.3, 73.1
90
th percentile IC50 9.3 17.0 22.4 24.9
Chloroquine
Median IC50 30.7 15.0 22.4 76.1
IC50 Range 1.4, 341.5 4.3, 205.5 8.1, 430.2 4.7, 455.0
90
th percentile IC50 199.4 108.2 199.1 364.6
Mefloquine
Median IC50 34.5 44.6 32.6 41.2
IC50 Range 1.6, 398.0 2.8, 92.1 9.2, 75.7 1.5, 191.5
90
th percentile IC50 84.6 62.5 59.0 82.4
IC50 values are in nM. IC50 Range = minimum IC50, maximum IC50.9 0
th
percentile IC50=I C 50 value of the 90
th percentile within the range of drug
responses observed each year.
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Ex vivo assays are an important tool for malaria drug re-
sistance monitoring in direct patient samples. These as-
says complement in vivo studies by allowing researchers
to test parasite responses to different drugs individually
and in the absence of patient factors that might intro-
duce noise or confound results. Importantly, ex vivo
monitoring of malaria parasite drug responses can pro-
vide an early warning of decreased parasite sensitivity
before parasites become highly resistant and cause in-
fected patients to fail drug treatment.
The DAPI ex vivo assay performed well, with excellent
agreement between technical replicates, good dynamic
range, and very good correlation between drug responses
measured ex vivo with those measured in vitro. Further-
more, the IC50 values observed in Thiès, Senegal be-
tween 2008 and 2011 were comparable to other ex vivo
studies of P. falciparum drug response [10,18,29]. Be-
cause parasite drug responses were measured over a
four-year time span, trends in drug response in this
population over time could also be assessed. The trends
observed in parasite responses to amodiaquine and
artemisinin suggest that malaria parasites in Thiès are
becoming more tolerant to these compounds. Data from
future years of ex vivo monitoring will be critical in de-
termining whether these trends continue.
The trends observed in the prevalence of resistance-
associated mutations in pfcrt and pfmdr1 suggest that
anti-malarial drug use is selecting for resistance-
associated alleles within this population. In contrast to
other studies [11,20,25], resistance-associated mutations
within pfcrt remained prevalent within this population,
and even appeared to increase in prevalence between
2010 and 2011. This suggests either that compensatory
mutations have restored the fitness of resistant parasites,
and/or that anti-malarial drug use is maintaining these
mutations within the population. The continuous distri-
bution of chloroquine IC50 values observed in 2008 and
2011 further suggests that additional mutations affecting
parasite drug response exist in this population. The find-
ing that parasites with mutations in pfcrt have higher
amodiaquine IC50 values is in agreement with previous
studies of laboratory parasite lines [26], and malaria-
infected patients [28]. Additionally, amodiaquine has been
Figure 3 Changes in prevalence of known drug resistance-associated mutations over time. Prevalence of resistance-associated mutations
in pfcrt (A) and pfmdr1 (B) with corresponding 95% point-wise confidence intervals. Mutations were measured by high-resolution melt (HRM)
technology and prevalence was calculated by dividing the number of samples containing at least one mutant allele by the total number of
samples genotyped each year. Asterisks indicate significant changes over time (P<0.05 by Fisher-Hamilton exact test).
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2003 [17]. Because increased amodiaquine IC50 values
were associated with the typed pfcrt mutations, it seems
possible that use of amodiaquine is preserving these muta-
tions within the population.
The observed trends in resistance mutations within
pfmdr1 suggest that artemisinin compounds are select-
ing for a combination of wild-type and mutant alleles
within this gene. The N86 and 184F alleles have been
previously associated with in vivo selection by ACT
[30,31], and two recent studies of the prevalence of drug
resistance markers in Dakar, Senegal also found a high
prevalence of the Y184F mutation [32,33]. Furthermore,
Y184F has been found to be under selection among
parasite populations in Cambodia [34], where artemisi-
nin resistance, defined as delayed parasite clearance, has
been described. While the artemisinin resistance pheno-
type of delayed in vivo parasite clearance does not ap-
pear to correlate well with ex vivo or standard in vitro
assays [2], artemisinin resistance might occur through
different mechanisms in Africa as compared to southeast
Asia. Furthermore, as parasites become increasingly ar-
temisinin resistant in vivo, they may become amenable
to monitoring with ex vivo assays such as this one. The
disappearance of the N86Y and N1042D mutations,
coupled with the rapid rise of the Y184F mutation,
suggest that selective pressure is acting on pfmdr1, elim-
inating some mutations while driving others to high
prevalence within this population. Because artemisinin
response was associated with all three of the typed
pfmdr1 mutations, it appears that the artemisinin deriva-
tives used in ACT might be the selective force driving
the Y184F mutation to high prevalence, while simultan-
eously selecting for the wild-type alleles at positions 86
and 1042.
These findings are consistent with the hypothesis that
amodiaquine use in Thiès, Senegal has selected for chloro-
quine resistance-associated mutations within pfcrt,w h i l e
artemisinin compounds have selected for a particular com-
bination of wild-type and mutant alleles within pfmdr1.I n
both cases, alleles that make parasites better able to with-
stand drug pressure are likely selected. Other African
countries that have used artesunate-amodiaquine have also
documented sustained high prevalence of chloroquine
resistance-associated mutations within pfcrt [35,36]. Con-
versely, countries deploying ACT that does not include
amodiaquine have seen a return to chloroquine-sensitivity
after chloroquine was removed from the treatment arsenal
[25,37], presumably due to the fitness costs of resistance-
associated mutations. Other African countries have also
documented recent increases in the prevalence of the
pfmdr1 N86 and 184F alleles [38,39], though this study
marks the highest recorded prevalence to date of the
Y184F mutation on the African continent.
Conclusions
Ex vivo monitoring of malaria parasite drug response is
a powerful tool for malaria control. Directly testing
Table 3 Associations between wild-type and mutant genotypes and ex vivo drug responses
Median IC50 Values
(Interquartile Range)
Amodiaquine Artemisinin Chloroquine Mefloquine
Allele Wild-type Mutant P Wild-type Mutant P Wild-type Mutant P Wild-type Mutant P
N(wt)/N(mut)
pfcrt 72-76
a 9 12 0.004 9 7 0.005 14 99 < 0.0001 42 36 0.3
160/182 (6,15) (8,19) (6,15) (4,10) (11,28) (53,196) (21,57) (21,52)
pfcrt A220S 9 12 0.0005 9 7 0.01 14 99 < 0.0001 42 36 0.3
163/174 (6,14) (8,19) (6,15) (4,10) (11,28) (53,196) (21,57) (21,52)
pfcrt N326S 10 15 0.01 8 9 0.6 28 139 < 0.0001 38 38 0.7
295/40 (7,16) (9,20) (5,13) (5,12) (13,93) (84,217) (21,54) (28,56)
pfmdr1 N86Y 10 9 0.6 8 5 0.0002 33 75 0.4 41 17 < 0.0001
296/37 (7,16) (6,17) (5,13) (3,8) (14,101) (12,201) (26,57) (9,22)
pfmdr1 Y184F 10 11 0.1 7 8 0.01 29 34 0.6 41 36 0.3
136/202 (6,16) (7,16) (4,11) (6,14) (12,109) (13,114) (21,58) (21,52)
pfmdr1 N1042D 10 8 0.1 8 4 <0.0001 33 47 1.0 38 38 0.9
307/31 (7,16) (5,16) (6,13) (2,5) (13,109) (15,115) (21,53) (18,59)
IC50 values are in nM. N(wt)= number of samples possessing only the wild-type allele. N(mut)= number of samples possessing at least one mutant allele. Mixed ge-
notypes were detected at the following prevalence: pfcrt 72-76 (n= 22); pfcrt A220S (n = 19); pfcrt N326S (n = 4); pfmdr1 N86Y (n = 7); pfmdr1 Y184F (n= 22); pfmdr1
N1042D (n= 1). Genotypes were determined by high-resolution melt (HRM) genotyping. P-values were calculated using the Wilcoxon rank-sum test, and associa-
tions where P< 0.05 are shown in bold.
apfcrt protein positions 72-76 were all perfectly correlated and were analysed as a haplotype rather than individually.
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associated mutations can provide early warnings of de-
creased parasite sensitivity to the individual drugs used
in combination therapies, before parasites become highly
resistant and cause infected patients to fail drug treat-
ment. Ex vivo drug assays such as the one used here
could also provide phenotype data for analyses aimed at
identifying additional drug resistance markers [40-42].
As ACT is the first-line treatment throughout Africa,
the ability to detect resistance to both artemisinin deriv-
atives and partner compounds as they emerge will be-
come increasingly important in order to preserve the
efficacy of these drugs.
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